Title:
Commercialization opportunity for an reactive scintillators with Mission Support and Test Services (MSTS).
Background Information:
A potent weapon for the destruction of cancerous tumors in the body has been photodynamic therapy using lasers where light can reach the cancer cells. One variant of these therapies uses a reagent that generates toxic levels of nitric oxide in targeted cells. Over the past several years, researchers have turned to X-rays as a method to deliver energy to deep tumors. MSTS has developed intellectual property for the combination of these two modalities with the potential to amplify the effects of X-ray radiation treatment and tumor destruction.
Opportunity Description:
MSTS possesses the intellectual property and know-how to develop reactive scintillators and is seeking partners in the development and commercialization effort of the system, validation testing, and potential regulatory approvals. Partners are sought to collaborate via Cooperative Research and Development Agreement (CRADA), commercial license agreement, or potential sale and assignment of IP rights. MSTS is available to collaborate with non-federal entities (NFEs) including Business, Industry and Non-Profits, Universities, and Government Agencies to leverage a broad spectrum of talent and capabilities.
Interested parties should contact MSTS Technology Partnerships and Intellectual Property Office via email with the subject line: Reactive Scintillators.
